Next Generation Sequencing Market to Reach $33.73 billion By 2028 Thanks to Increased Attention Early Disease Diagnosis and High Prevalence of Cancer…

SkyQuest Technology Consulting Pvt. Ltd.

Global next generation sequencing market was valued at $10.28 billion in 2021, and it is expected to reach a value of $33.73 billion by 2028, at a CAGR of 18.50% over the forecast period (20222028).

Westford, USA, July 13, 2022 (GLOBE NEWSWIRE) -- Next generation sequencing (NGS) is a game-changing technology that is revolutionizing how we study and understand biology. NGS allows us to sequence vast amounts of DNA or RNA much faster and more cheaply than ever before, making it possible to generate unprecedented amounts of data about the genomes of organisms. The demand for NGS services in the global next generation sequencing market has been growing rapidly in recent years, as the technology has become more affordable and accessible. A wide variety of scientific disciplines are now using NGS, including human genomics, cancer research, microbiology, evolutionary biology, agriculture, and many others. The number of publications featuring NGS data has also been increasing rapidly in recent years.

One of the key factors driving the growth of the next generation sequencing market is the ongoing need for better methods for diagnosing and treating diseases. For example, NGS can be used to detect genetic variations that may be associated with disease risk. It can also be used to identify novel drug targets and develop personalized medicines. In addition, NGS is playing an increasingly important role in basic research as scientists strive to understand the complexities of genome function.

Next Generation Sequencing: A Magic Wand for Early Diagnosis of Cancer

The global prevalence of cancer is alarmingly high, with an estimated 17 million new cases and 10 million deaths in 2020 alone. The World Health Organization (WHO) predicts that these figures will rise to 27 million new cases and 16.3 million deaths by 2040 if current trends continue. Early detection of cancer through screening programs is one of the most effective ways to reduce the burden of this disease, as it can lead to earlier diagnosis and treatment, which can improve survival rates significantly. Apart from this, more than 400,000 children develop cancer every year.

Story continues

The next generation of sequencing technology is often heralded as a magic wand for the early diagnosis of cancer. This is because it has the potential to provide rapid and accurate identification of tumors at an early stage, when they are most treatable. Next generation sequencing (NGS) technology intervenes at the level of DNA, providing information on genetic variation within a tumor. This can be used to detect early-stage cancers that may not yet have developed symptoms or detectable changes at the cellular level. The Global next generation sequencing market is also gaining demand for monitoring the progression of a cancer, and to assess how well treatments are working.

There are several reasons why NGS is seen as such a powerful tool in cancer diagnosis and treatment. First, it is extremely sensitive and can detect very small amounts of DNA from a tumor. Second, it can rapidly generate large amounts of data, which can be used to identify even rare mutations that may be associated with cancer. Finally, NGS is relatively simple and inexpensive to perform, making it widely accessible across the global next generation sequencing market from almost all strata of society, especially in developed market like the US, the UK, and Germany, among others. Despite all these advantages, there are still some challenges associated with the use of NGS in cancer diagnosis and treatment. While NGS can identify DNA alterations that may be associated with cancer.

Get sample copy of this report:

https://skyquestt.com/sample-request/next-generation-sequencing-market

Next Generation Sequencing is Becoming Popular among Parents to Check Inborn Errors

As more and more parents learn about the benefits of next generation sequencing (NGS), its popularity is growing as a tool to check for inborn errors. NGS can provide a more comprehensive picture of a child's health, allowing parents to catch potential problems early and get their children the treatment they need. While NGS is not yet perfect, it is becoming more reliable and affordable as technology improves. As more parents learn about its potential, next generation sequencing market is likely to become even more popular as a way to keep children healthy and catch problems early.

As the technology for DNA sequencing gets cheaper and more sophisticated, an increasing number of parents are opting to have their child's genome sequenced at birth. This is especially true for parents who have a family history of genetic diseases. Sequencing the genome of a newborn is becoming more popular as the technology gets cheaper and more sophisticated. Inborn errors of metabolism are a group of rare genetic disorders that can cause serious health problems. Many of these disorders in the global next generation sequencing market are difficult to diagnose, and they often go undetected until something goes wrong.

According to the National Institutes of Health, about 25% of all live births in the United States each year are affected by at least one hereditary disease. However, the prevalence of these disorders varies widely, depending on the specific condition. For example, conditions like cystic fibrosis and sickle cell disease are relatively common, while others like Huntingtons disease are much rarer.

There are many different types of hereditary diseases, and they can affect any organ or system in the body. Some of the more common conditions include heart defects, respiratory problems, mental retardation, metabolic disorders, and cancer. Many of these disorders are life-threatening or cause significant disability, so it is important to be aware if any family members who have been affected by them. As a result, people are increasingly focusing getting their genome sequenced to know if they are carrying any gene that can lead to cancer.

With advancement in the next generation sequencing market, parents can now choose to have their child's genome sequenced at birth. This gives them the ability to catch these disorders early and start treatment immediately. It also allows them to make informed decisions about their child's future health. Although the cost of sequencing a genome is still relatively high, it is dropping rapidly. And as the technology continues to improve, it is expected that more parents will choose to have their child's genome sequenced at birth.

Food Industry to Offer Lucrative Opportunity for Next Generation Sequencing Market as Safety Concern Rises

The application of next generation sequencing in food safety and quality is an area of great interest and promise. The use of next generation sequencing technologies has the potential to revolutionize how we monitor food safety and quality. By providing rapid and high-throughput sequence data, next generation sequencing can be used to detect pathogens and other microorganisms in food more quickly and accurately than ever before. Additionally, the application of next generation sequencing can help us to better understand the genetic basis of food spoilage and contamination.

Growing concern about food safety has led to stricter quality control measures in the food industry. In particular, there is a greater focus on ensuring that food products are free from contaminants and meet safety standards, which is offering a lucrative opportunity for the players active in the next generation sequencing market to make most out of it. To this end, food manufacturers are increasingly adopting quality management systems such as Hazard Analysis and Critical Control Points (HACCP). These systems help to identify and control potential hazards at all stages of the food production process, from raw materials to finished products.

There are many different applications of next generation sequencing market in food safety and quality. One example is the use of next generation sequencing for pathogen detection. Pathogens are a major cause of foodborne illness, and traditional methods for detecting them often have low sensitivity or take too long to provide results. However, next generation sequencing can be used to rapidly detect pathogens in food samples with high accuracy. This information can then be used to taking steps to prevent outbreaks before they occur. In addition to pathogen detection, another important application of next generation sequencing is monitoring antibiotic resistance in bacteria present in food items. Antibiotic resistance is a growing public health concern, as it makes infections harder to treat and increases the risk of potentially deadly superbugs infection.

Browse summary of the report and Complete Table of Contents (ToC):

https://skyquestt.com/report/next-generation-sequencing-market

AI and Accelerated Computing to Bring Down the Cost of Next Generation Sequencing to Less Than $300

AI and accelerated computing are already enabling a wide range of new applications in genomics. One such application is next generation sequencing (NGS), which is used to determine the order of nucleotides in DNA. NGS is currently used for a variety of purposes, including diagnosing genetic diseases, determining ancestry, and predicting drug response in the global next generation sequencing market. The cost of NGS has fallen dramatically in recent years, from $5.6 billion per genome in 2001 to less than $1,000 today. However, there is still room for further improvement.

AI and accelerated computing can help bring down the cost of NGS by making it more efficient. For example, AI can be used to streamline the process of sequence alignment, which is often the most time-consuming and computationally intensive step in NGS. In addition, accelerated computing can be used to speed up other parts of the NGS process, such as variant calling and read mapping. The combination of AI and accelerated computing has the potential to reduce the cost of NGS even further, to less than $300 per genome. This would make it affordable for many more people to access this important technology.

Top 10 Biologics Companies in the US Raised Over 1.65 billion in 2021, but Ultima Genomics took the Larger Piece of Pie

These companies in the global next generation sequencing market are working on developing new treatments and cures for a variety of diseases and conditions. Some of the diseases that they are targeting include cancer, Alzheimers disease, Parkinsons disease, and multiple sclerosis. The amount of money that these companies have raised shows how important it is to find new treatments for these diseases. The hope is that with this additional funding, these companies will be able to make even more progress in developing new therapies and cures. In May 2022, the company managed to raise $600 million through private equity. The company is planning to use this funding to bring down the NGS to $100 in the years to come. Apart from this, Kriya Therapeutics, Moma Therapeutics, and Aspen Neuroscience raised around $270 million, and 150 million, $147.5 million, respectively. All three of these companies are working on cutting-edge therapies that have the potential to change the lives of patients suffering from these devastating diseases. Apart from this, these company are holding major market share as they have established themselves in the market.

It is clear that biologics research is an area where there is a lot of interest and investment is coming in the global next generation sequencing market. This is good news for patients who are waiting for new treatments and cures. With more funding available, these top companies should be able to make even more progress in finding new ways to treat.

Ultima Genomics is a new biotech company that is working on cutting the cost of sequencing the human genome. Theyve created a powerful technology called named Triple X that adjusts itself by integrating new data and machine learning to bring down the cost. The first use for this companys pitch will be whole-genome sequencing, which can also be applied to other approaches like single-cell and methylation sequencing.

Speak to Analyst for your custom requirements:

https://skyquestt.com/speak-with-analyst/next-generation-sequencing-market

Key Vendors in Next Generation Sequencing Market

PerkinElmer Inc. (US)

BGI Group (China)

Agilent Technologies Inc. (US)

Eurofins Scientific SE (Luxembourg)

Pacific Biosciences of California Inc. (US)

Oxford Nanopore Technologies (UK)

QIAGEN NV (Netherlands)

F. Hoffmann-La Roche AG (Switzerland)

GENEWIZ Inc. (US)

Psomagen, Inc. (South Korea)

10x Genomics Inc. (US)

Takara Bio (Japan)

Zymo Research (US)

NuGen Technologies (US)

Hamilton Company (US)

Beckman Coulter (US)

Becton, Dickinson, and Company (US)

Lucigen Corporation (US)

Novogene Co., Ltd. (China)

Related Reports in SkyQuests Library:

Global Medical Tourism Market

Global Home Healthcare Market

Global Consumer Healthcare Market

Global Healthcare Consulting Services Market

Global 3D Cell Culture Market

About Us:

SkyQuest Technologyis leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.

Address:

1 Apache Way, Westford, Massachusetts 01886

Phone:

USA (+1) 617-230-0741

Email:sales@skyquestt.com

LinkedInFacebookTwitter

Here is the original post:
Next Generation Sequencing Market to Reach $33.73 billion By 2028 Thanks to Increased Attention Early Disease Diagnosis and High Prevalence of Cancer...